Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 15, 2001, Pages 67-70

  Tolcher, Anthony W ^a,b  

^a CTRC Institute for Drug Development   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; DOCETAXEL; ESTRAMUSTINE; OBLIMERSEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; FATIGUE; HUMAN; MALE; MALE GENITAL TRACT CANCER; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 0034794290     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.26906     Document Type: Article

References (20)

1. Cancer statistics, 2001
2. Cancer statistics by race and ethnicity
3. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
4. Mitoxantrone: Modest activity in a phase II trial in advanced prostate cancer
5. 14-Day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate
6. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer
7. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers
8. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
9. Bcl-2 and the regulation of programmed cell death
10. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
11. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
12. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2
13. Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis
14. Phase I trial of docetaxel with estramustine in androgen- independent prostate cancer
15. Phase I/II study of the combination of estramustine phosphate (Emcyt®) plus docetaxel (Taxotere®) (DT) in patients with hormone refractory prostate cancer (HRPC)
16. Inactivation of bcl-2 by phosphorylation
17. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
18. Bcl2 is the guardian of microtubule integrity
19. Antisense bcl-2 oligonucleotides inhibit the progression to androgen-independence (Al) after castration in the LNCaP tumor model
20. Antisense bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model